Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC plus FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial
dc.contributor.author | Lamarca, Angela | |
dc.contributor.author | Palmer, D. | |
dc.contributor.author | Wasan, H. S. | |
dc.contributor.author | Ross, P. | |
dc.contributor.author | Ma, Y. T. | |
dc.contributor.author | Arora, A. | |
dc.contributor.author | Falk, S. | |
dc.contributor.author | Gillmore, R. | |
dc.contributor.author | Wadsley, J. | |
dc.contributor.author | Patel, K. | |
dc.contributor.author | Anthoney, A. | |
dc.contributor.author | Maravellas, A. | |
dc.contributor.author | Waters, J. S. C. | |
dc.contributor.author | Hoobs, C. | |
dc.contributor.author | Macdonald, T. | |
dc.contributor.author | Ryder, D. | |
dc.contributor.author | Ramage, J. | |
dc.contributor.author | Davies, L. | |
dc.contributor.author | Bridgewater, J. A. | |
dc.contributor.author | Valle, Juan W | |
dc.date.accessioned | 2023-01-24T10:32:19Z | |
dc.date.available | 2023-01-24T10:32:19Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Lamarca A, Palmer D, Wasan HS, Ross P, Ma YT, Arora A, et al. Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC plus FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial. Annals of Oncology. 2022 Sep;33(7):S564-S5. PubMed PMID: WOS:000866211600054. | en |
dc.identifier.doi | 10.1016/j.annonc.2022.07.082 | en |
dc.identifier.uri | http://hdl.handle.net/10541/625948 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.annonc.2022.07.082 | en |
dc.title | Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC plus FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | en] |